二甲基双十八烷基铵 | 14357-21-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 二甲基双十八烷基铵
• 中文别名: 二甲基二十八烷基铵
• 英文名称: dioctadecyldimethylammonium
• 英文别名: dimethyl-(dioctadecyl)-ammonium；dimethyldioctadecylammonium cation；dimethyl dioctadecylammonium；dimethyldioctadecylammonium；DISTEARYLDIMETHYLAMMONIUM；Dimethyl-dioctadecyl-ammonium；dimethyl(dioctadecyl)azanium
• CAS: 14357-21-2
• 化学式: C₃₈H₈₀N
• 分子量: 551.06
• InChiKey: OGQYPPBGSLZBEG-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  17.9
• 重原子数：
  39
• 可旋转键数：
  34
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2923900090

反应信息

• 作为反应物：
  描述：

  nonasodium decatungstoeuropate 32-hydrate 、 二甲基双十八烷基铵 以 乙醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  A direct imaging of amphiphilic catalysts assembled at the interface of emulsion droplets using fluorescence microscopy

  摘要：

  该催化剂在以 H2O2 为氧化剂的醇类氧化过程中表现出很高的选择性和活性，而且催化剂可以通过破乳作用轻松分离和回收。

  DOI：

  10.1039/b713831h
• 作为试剂：
  描述：

  4-叔丁基环己酮 在 二甲基双十八烷基铵 、 ⁺ClO4^- 、 lithium taeniorite 、 氢溴酸 氢气 作用下， 以 甲醇 为溶剂， 29.85 ℃ 、101.0 kPa 条件下， 反应 24.0h， 生成 3-(TERT-BUTYL)-1-(MESITYLMETHYL)-1H-PYRAZOLE-5-CARBOXYLIC ACID
  参考文献：
  名称：

  New Clay-Supported Chiral Rhodium Complexes: Interlayer Modification with Structural Tuning Guests and Asymmetric Hydrogenation

  摘要：

  合成了新型的宿主- Guests 催化剂，其中手性铑络合物插入了修饰过的层状黏土中，观察到催化活性会因客体分子的取向而发生剧烈变化。

  DOI：

  10.1246/cl.1998.1191

文献信息

• [EN] PHENOTHIAZINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE PHÉNOTHIAZINE ET LEURS UTILISATIONS
  申请人：CAMP4 THERAPEUTICS CORP

  公开号：WO2019195789A1

  公开（公告）日：2019-10-10

  The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).

  本发明提供了吩噻嗪化合物，其制备方法，包含该化合物的药物组合物，以及在治疗各种疾病或症状中使用该化合物或组合物，例如核糖体紊乱和核糖体病，例如钻石-布莱克范贫血（DBA）。
• COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES
  申请人：Lin Paulo J.C.

  公开号：US20120264810A1

  公开（公告）日：2012-10-18

  Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\ the cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound that enhances uptake of the lipid particles b\ the cell The methods and compositions are useful in delivering a therapeutic agent to a cell, e g for the treatment of a disease or disorder in a subject

  描述了用于增强细胞对脂质粒的摄取的组成物、方法和化合物。在特定的实施例中，发明的方法包括将细胞与脂质粒和一种与Na+/K+ ATPase结合的化合物接触，以增强细胞对脂质粒的摄取。在实践方法中使用的相关组成物包括包含一种共轭化合物的脂质粒，该共轭化合物增强细胞对脂质粒的摄取。这些方法和组成物可用于将治疗剂递送到细胞中，例如用于治疗主体中的疾病或失调。
• Silanol Compound, Composition, and Method for Producing Silanol Compound
  申请人：NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY

  公开号：US20170183363A1

  公开（公告）日：2017-06-29

  The purpose of the present invention is to provide silanol compounds that can be used as raw materials of siloxane compounds and the like, and a composition of the silanol compounds, as well as to provide a production method that makes it possible to produce silanol compounds at excellent yield. A composition comprising 5 mass % to 100 mass % of a silanol compound represented by Formulas (A) to (C) can be prepared by devising to produce silanol compounds under water-free conditions, to produce silanol compounds in a solvent having the effect of suppressing the condensation of silanol compounds, and to perform other such processes, the composition being able to be used as a raw material or the like of siloxane compounds because the silanol compounds can be stably present in the resulting composition.

  本发明的目的是提供可用作硅氧烷化合物等原料的硅醇化合物，以及硅醇化合物的组合物，并提供一种能够以优异产率生产硅醇化合物的生产方法。通过设计在无水条件下生产硅醇化合物，使用具有抑制硅醇化合物缩合作用的溶剂生产硅醇化合物，并执行其他类似过程，可以制备包含按照(A)至(C)式表示的硅醇化合物质量百分含量为5%至100%的组合物。由于硅醇化合物可以稳定存在于所得组合物中，因此该组合物可用作硅氧烷化合物等的原料。
• SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA
  申请人：PROTIVA BIOTHERAPEUTICS, INC.

  公开号：US20160115483A1

  公开（公告）日：2016-04-28

  The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.

  本发明提供了包含干扰RNA（例如siRNA、aiRNA、miRNA）的组合物，其靶向波洛样激酶1（PLK-1）表达，并提供了使用这种组合物来沉默PLK-1表达的方法。更具体地说，本发明提供了未修饰和化学修饰的干扰RNA分子，这些分子可以沉默PLK-1表达，并提供了它们的使用方法。本发明还提供了含有干扰RNA分子、阳离子脂质和非阳离子脂质的血清稳定核酸-脂质颗粒（例如SNALP），这些颗粒还可以进一步包含抑制颗粒聚集的共轭脂质。本发明还提供了通过向哺乳动物主体施用本文描述的干扰RNA分子来沉默PLK-1基因表达的方法。本发明还提供了识别和/或修改具有免疫刺激性能的PLK-1干扰RNA的方法。此外，还提供了一种通过顺序输送PLK-1干扰RNA后接着化疗药物来使细胞（如癌细胞）对化疗药物产生敏感性的方法。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。

表征谱图